- First and only continuous glucose monitoring (CGM) system with
expanded coverage in Japan will
enable more people with diabetes to manage their condition without
routine fingersticks1 associated with traditional blood
glucose monitoring
- Without expanded coverage, CGM reimbursements are limited to
segment of people with diabetes who require insulin multiple times
a day
ABBOTT PARK, Ill.,
March 24, 2022
/PRNewswire/ -- Abbott (NYSE: ABT) today announced that the
Japanese Ministry of Health, Labour and Welfare has approved the
expansion of reimbursement coverage for its FreeStyle® Libre system
to include all people with diabetes who use insulin at least once a
day.
The expanded coverage will enable more people with diabetes to
access the glucose data needed to manage their condition without
the routine fingersticks1 associated with traditional blood glucose
monitoring.
"The best healthcare solution is the one that helps the most
people, which is why we designed our FreeStyle Libre system with
access and affordability in mind from the very beginning," said
Jared Watkin, senior vice president
of Abbott's diabetes care business. "FreeStyle Libre systems
provide a complete and comprehensive glucose picture without the
need for routine fingersticks. The technology helps enable behavior
change, which ultimately helps people live better, fuller
lives."
The reimbursement expansion, which will go into effect
April 1, 2022, was granted based on
FreeStyle Libre's overall value proposition, which includes ease of
use and scientific evidence that shows the clinical benefits of
using the FreeStyle Libre system among all people who take
self-injections of insulin.2,3,4
"With the expanded reimbursement coverage, healthcare
professionals like me will be equipped with continuous glucose
monitoring information and actionable insights for patients with
diabetes, which has previously been available mainly to a limited
population of people who require multiple daily injections of
insulin. This will allow patients to have a better understanding
and control of their diabetes based on glucose fluctuation through
continuous monitoring," said Dr. Wataru
Ogawa, professor, Division of Diabetes and Digestive and
Kidney Diseases, Kobe University Graduate School of Medicine. "I am
expecting this will lead to better management of my patients'
overall condition, as well as reduce the future risks of
diabetes-related complications."
About Abbott
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 113,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews.
1 A fingerstick test using a blood glucose meter is
required when there are questions on the accuracy of the
interstitial fluid glucose levels or impending hypoglycaemia or
hypoglycaemia as reported by the system or when symptoms do not
match the system readings.
2 Miller, Brandner et al. HbA1c Reduction After
Initiation of the FreeStyle Libre System in Type 2 Diabetes
Patients on Long-Acting Insulin or Non-Insulin Therapy.
3 Miller et al. FreeStyle Libre System Use Associated
with Reduction in Acute Diabetes Events and All-Cause
Hospitalizations in Patients with Type 2 Diabetes Without Bolus
Insulin.
4 Wright et al. HbA1c Reduction Associated with a
FreeStyle Libre System in People with Type 2 Diabetes Not on Bolus
Insulin Therapy.
View original
content:https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-is-first-and-only-cgm-system-to-gain-expanded-reimbursement-in-japan-to-include-all-people-with-diabetes-who-use-insulin-301509715.html
SOURCE Abbott